COVID-19–Related Outcomes in Primary Mitochondrial Diseases

Author:

Pizzamiglio ChiaraORCID,Machado Pedro M.ORCID,Thomas Rhys H.ORCID,Gorman Gráinne S.,McFarland RobertORCID,Hanna Michael G.,Pitceathly Robert D. S.ORCID,

Abstract

Background and ObjectivesTo identify factors associated with severe coronavirus disease 2019 (COVID-19), defined by hospitalization status, in patients with primary mitochondrial diseases (PMDs), thereby enabling future risk stratification and informed management decisions.MethodsWe undertook a cross-sectional, international, registry-based study. Data were extracted from the International Neuromuscular COVID-19 Database and collected between May 1, 2020, and May 31, 2021. The database included subjects with (1) PMD diagnosis (any age), clinically/histopathologically suspected and/or genetically confirmed; and (2) COVID-19 diagnosis classified as “confirmed”, “probable”, or “suspected” based on World Health Organization definitions. The primary outcome was hospitalization because of COVID-19. We collected demographic information, smoking status, coexisting comorbidities, outcomes after COVID-19 infection, and PMD genotype-phenotype. Baseline status was assessed using the modified Rankin scale (mRS) and the Newcastle Mitochondrial Disease Adult Scale (NMDAS).ResultsSeventy-nine subjects with PMDs from 10 countries were included (mean age 41.5 ± 18 years): 25 (32%) were hospitalized, 48 (61%) recovered fully, 28 (35%) improved with sequelae, and 3 (4%) died. Statistically significant differences in hospitalization status were observed in baseline status, including the NMDAS score (p = 0.003) and mRS (p = 0.001), presence of respiratory dysfunction (p < 0.001), neurologic involvement (p = 0.003), and more than 4 comorbidities (p = 0.002). In multivariable analysis, respiratory dysfunction was independently associated with COVID-19 hospitalization (odds ratio, 7.66; 95% CI, 2–28; p = 0.002).DiscussionRespiratory dysfunction is an independent risk factor for severe COVID-19 in PMDs while high disease burden and coexisting comorbidities contribute toward COVID-19–related hospitalization. These findings will enable risk stratification and informed management decisions for this vulnerable population.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Neurology (clinical)

Reference13 articles.

1. A neurological perspective on mitochondrial disease

2. Get support if you’re clinically extremely vulnerable to coronavirus (COVID-19). GOV.UK. Accessed August 1, 2021. gov.uk/coronavirus-shielding-support.

3. Interim Operational Considerations for Implementing the Shielding Approach to Prevent COVID-19 Infections in Humanitarian Settings. Centers for Disease Control and Prevention (CDC). Accessed August 1, 2021. cdc.gov/coronavirus/2019-ncov/global-covid-19/shielding-approach-humanitarian.html.

4. Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome;Keddie;Brain.,2021

5. World Health Organization. (2020). Coronavirus Disease 2019 (COVID-19): Situation Report, 61. World Health Organization

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3